淋巴瘤CD30免疫组织化学检测及结果判读规范

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas

CD30可在多种淋巴瘤中表达,其中经典型霍奇金淋巴瘤(classical Hodgkin lymphoma,CHL)和间变性大细胞淋巴瘤(anaplastic large cell lymphoma,ALCL)最为常见。近年来,靶向CD30的抗体药物偶联物维布妥昔单抗已获批应用于复发/难治性CHL和ALCL患者的治疗,并取得显著疗效。然而,该靶向治疗药物能否使其他类型淋巴瘤患者获益目前尚不明确,精确评估CD30表达水平对此类淋巴瘤患者的临床试验和个体化治疗有重要的指导意义。目前,CD30检测仍主要通过免疫组织化学染色的方法,尚缺乏统一、规范的检测流程及结果判读标准。本文通过分析CD30的检测现状,联合多中心研究探索CD30免疫组织化学检测流程及结果判读方法,并结合文献和专家经验,最终达成淋巴瘤CD30免疫组织化学检测及结果判读共识,希望能有助于淋巴瘤CD30表达的规范化检测。

CD30 can be expressed in a variety of lymphoma subtypes,among which classical Hodgkin lymphoma(CHL)and anaplastic large cell lymphoma(ALCL)are the most common ones.Recently,Brentuximab vedotin,the antibody-drug conjugate targeting CD30,has been approved in the treatment of patients with refractory and relapsed CHL and ALCL,and has achieved significant curative effect.However,whether CD30-targeted therapy could benefit patients with other types of lymphoma remains largely unknown.Accurate evaluation of the expression level of CD30 may thus have important guiding significance for the clinical trials and individualized treatment of patients with those lymphomas.To date,CD30 detection is mainly via immunohistochemical staining,however,with no unified and standardized process and interpretation method.We herein described the current status on CD30 testing,and explored the procedures of immunohistochemical detection and interpretation of the results through multicentric studies.A consensus was finally reached,which was based on the combination of our research results,literature review,experts’experience,and internal discussion among the panel members,and might hopefully contribute to standardization of the immunohistochemical detection and interpretation of CD30 expression in lymphomas.